Skip to content
SmartFigure
WhiteOak Capital Mutual Fund

WhiteOak Capital Pharma and Healthcare Fund

WhiteOak Capital Mutual Fund · Direct plan · Growth

  • Equity
  • Sectoral / Thematic Fund
  • Very High Risk
1-year returns
26.3%
NAV
₹18.46
▲ 0.08% · 13 Nov 2026
Fund size
₹927 Cr
Expense ratio
1.09%
a year
Minimum SIP
₹100

Figures are for the Direct plan. The Regular plan, bought through a distributor, is at ₹17.59 and has returned 24.19% over a year.

Returns, and where it stands

Against the average sectoral / thematic fund, and its place among them. Anything longer than a year is a yearly rate.

PeriodThis fundCategoryRank
1 year26.3%6.1%ahead7 of 226
Every period, and the Regular plan →
PeriodDirectRegular
1 month9.2%9.1%
3 months5%4.5%
6 months19.9%18.8%
1 year26.3%24.2%
2 yearsp.a.19.9%17.9%

Figures are for the Direct plan, and the rank compares it against the same plan of its peers, best first. Based on NAV history from Feb 2024.

Plan

NAV history

▲ 26.34% in the last 1Y

13.515.918.413 Nov 202515 May 202613 Nov 2026

Hover or tap the chart for the NAV on any date. Past NAVs are adjusted for unit splits.

If you had invested in this fund

Investment type
₹
years
Total invested
₹1,20,000
Gain
₹34,494
XIRR (per year)
26.43%
Value today
₹1,54,494

24 monthly instalments from 14 Nov 2024, valued at the latest NAV. Past returns do not guarantee future returns.

What the ride has been like

Worked out from this fund's own NAV history, not a rating.

How bumpy
14.5% a year
1.3% less than the category average — the steadier side
Worst fall so far
−15.4%
Jan 2025 to Feb 2025.
Years that made money
100%
Of every one-year stretch it has been through.

Fund details

Minimum lumpsum
₹500
Minimum top-up
₹500
Lock-in
None
Plan started
6 Feb 2024
Portfolio turnover
1.79x
Expense ratio
1.09%
as of 30 Sept 2026

Managed by Piyush Baranwal, Ramesh Mantri, Trupti Agrawal, Dheeresh Pathak, Ashish Agrawal

Direct plan figures, last checked on 7 Nov 2026. Exit load and the scheme's benchmark are in thescheme document.

How it compares

WhiteOak Capital Pharma and Healthcare Fund against other funds in the Sectoral / Thematic Fund category
Fund1Y3Y5YExpenseFund size
Nippon India Taiwan Equity Fund60.64%46.52%–1.06%₹1,147 Cr
HDFC Defence Fund20.34%33.64%–0.89%₹11,493 Cr
HDFC Pharma and Healthcare Fund31.6%31.28%–1.03%₹3,501 Cr
SBI Healthcare Opportunities Fund26.07%25.42%20.65%1.01%₹5,870 Cr
HDFC Transportation and Logistics Fund10.1%24.77%–1.1%₹2,043 Cr
Mirae Asset Healthcare Fund27.89%24.42%17.87%0.62%₹3,494 Cr
WhiteOak Capital Pharma and Healthcare Fund26.34%––1.09%₹927 Cr

About WhiteOak Capital Pharma and Healthcare Fund

WhiteOak Capital Pharma and Healthcare Fund is a sectoral / thematic fund managed by WhiteOak Capital Mutual Fund. Invest in one sector (such as banking, IT or pharma) or a theme (such as consumption or infrastructure). Concentrated and higher risk; suited to investors with a view on that sector.

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.

The scheme's stated objective, as published by WhiteOak Capital Mutual Fund.

The NAV (net asset value) is the price of one unit of the fund. It is published by the fund house every business day and changes with the value of the fund's holdings. The Growth option reinvests all gains, so its NAV reflects the fund's total return.

Tax on your gains

Gains are taxed as equity: sell within 12 months and the gain is short-term, taxed at 20%. Hold longer and it is long-term, taxed at 12.5% on gains above ₹1.25 lakh in a financial year, across all your equity investments.

Work out what you would owe with the capital gains tax calculator.

Every plan and option, with scheme codes
PlanOptionNAVScheme code
DirectGrowth Option₹18.455152349
RegularGrowth Option₹17.587152348

Frequently asked questions

What is the NAV of WhiteOak Capital Pharma and Healthcare Fund today?

The NAV of WhiteOak Capital Pharma and Healthcare Fund (Direct plan, Growth) is ₹18.455 and the Regular plan NAV is ₹17.587, as of 13 Nov 2026.

What returns has WhiteOak Capital Pharma and Healthcare Fund given?

Over the last year the Direct plan returned 26.34%. Past returns do not guarantee future returns.

What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund?

The Direct plan charges 1.09% a year, as disclosed on 30 Sept 2026. The fee is already taken out of the NAV, so the returns above are what you keep.

What is the minimum SIP amount in WhiteOak Capital Pharma and Healthcare Fund?

You can start a monthly SIP with ₹100, or invest a lump sum of ₹500 or more.

How much has WhiteOak Capital Pharma and Healthcare Fund fallen in the past?

Its deepest fall was 15.4% from 2 Jan 2025 to 28 Feb 2025. Of every one-year stretch in its history, 100% ended in a gain.

Which category does WhiteOak Capital Pharma and Healthcare Fund belong to?

It is a Sectoral / Thematic Fund from WhiteOak Capital Mutual Fund. Invest in one sector (such as banking, IT or pharma) or a theme (such as consumption or infrastructure). Concentrated and higher risk; suited to investors with a view on that sector.

What is the difference between the Direct and Regular plan?

Both invest in the same portfolio. The Direct plan is bought straight from the fund house or a direct platform and has a lower expense ratio because no distributor commission is paid, so its NAV grows slightly faster over time.

How are gains from WhiteOak Capital Pharma and Healthcare Fund taxed?

Gains are taxed as equity: sell within 12 months and the gain is short-term, taxed at 20%. Hold longer and it is long-term, taxed at 12.5% on gains above ₹1.25 lakh in a financial year, across all your equity investments.

Source: NAVs published by the fund house through AMFI. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not guarantee future returns. This page is for information only and is not a recommendation to buy or sell.